The litigation, captioned Taher Basma v. GeneDx Holdings Corp., centers on allegations that the genetic testing firm issued misleading statements regarding its $51 million acquisition of Fabric Genomics. While GeneDx touted the deal as a gateway to scalable revenue and AI-driven growth, the complaint alleges that leadership failed to disclose significant viability issues surrounding the acquired company.

Market confidence collapsed on May 4, 2026, when GeneDx reported its first-quarter results. The company revealed a sharp decline in adjusted gross margins and lower-than-expected reimbursement rates. Most notably, GeneDx disclosed a $31.3 million impairment loss tied to Fabric—nearly the entire initial cash outlay for the acquisition. Following the disclosure, the company’s share price plummeted by more than 49%. Investors seeking to discuss their legal rights or participate in the action may contact Kessler Topaz Meltzer & Check, LLP, which is representing potential claimants.